Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Receives $30.00 Average Price Target from Brokerages

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDXGet Rating) has been given a consensus recommendation of “Hold” by the seven brokerages that are covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and three have issued a buy recommendation on the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $30.00.

SNDX has been the topic of several recent research reports. Robert W. Baird lifted their target price on shares of Syndax Pharmaceuticals to $32.00 in a research report on Monday, August 15th. The Goldman Sachs Group dropped their price target on shares of Syndax Pharmaceuticals from $40.00 to $35.00 and set a “buy” rating on the stock in a research report on Tuesday, August 9th. Finally, B. Riley restated a “buy” rating and issued a $31.00 price target on shares of Syndax Pharmaceuticals in a research report on Thursday, July 28th.

Syndax Pharmaceuticals Stock Down 5.8 %

NASDAQ:SNDX opened at $23.14 on Friday. The firm’s 50 day simple moving average is $22.52 and its 200 day simple moving average is $18.91. The company has a debt-to-equity ratio of 0.04, a current ratio of 12.69 and a quick ratio of 12.69. Syndax Pharmaceuticals has a one year low of $13.27 and a one year high of $25.71. The company has a market cap of $1.31 billion, a PE ratio of 144.63 and a beta of 1.24.

Syndax Pharmaceuticals (NASDAQ:SNDXGet Rating) last posted its earnings results on Monday, August 8th. The company reported ($0.62) EPS for the quarter, topping the consensus estimate of ($0.65) by $0.03. Syndax Pharmaceuticals had a net margin of 17.84% and a return on equity of 0.24%. On average, research analysts anticipate that Syndax Pharmaceuticals will post -2.66 earnings per share for the current year.

Insider Transactions at Syndax Pharmaceuticals

In other news, insider Briggs Morrison sold 62,292 shares of Syndax Pharmaceuticals stock in a transaction on Friday, July 1st. The shares were sold at an average price of $19.00, for a total value of $1,183,548.00. Following the completion of the sale, the insider now owns 17,836 shares in the company, valued at approximately $338,884. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, insider Briggs Morrison sold 62,292 shares of Syndax Pharmaceuticals stock in a transaction on Friday, July 1st. The shares were sold at an average price of $19.00, for a total value of $1,183,548.00. Following the completion of the sale, the insider now owns 17,836 shares in the company, valued at approximately $338,884. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Peter Ordentlich sold 25,000 shares of Syndax Pharmaceuticals stock in a transaction on Wednesday, August 24th. The shares were sold at an average price of $25.04, for a total transaction of $626,000.00. Following the completion of the sale, the insider now owns 265 shares of the company’s stock, valued at approximately $6,635.60. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 197,744 shares of company stock worth $4,373,715. Company insiders own 6.30% of the company’s stock.

Institutional Trading of Syndax Pharmaceuticals

Several hedge funds have recently modified their holdings of SNDX. Point72 Hong Kong Ltd bought a new stake in Syndax Pharmaceuticals during the 1st quarter valued at $41,000. Prospera Financial Services Inc bought a new stake in Syndax Pharmaceuticals during the 1st quarter valued at $66,000. Amalgamated Bank bought a new stake in Syndax Pharmaceuticals during the 1st quarter valued at $102,000. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in Syndax Pharmaceuticals by 60.4% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 8,460 shares of the company’s stock valued at $163,000 after purchasing an additional 3,187 shares in the last quarter. Finally, Martingale Asset Management L P bought a new stake in Syndax Pharmaceuticals during the 2nd quarter valued at $195,000. Institutional investors own 97.81% of the company’s stock.

Syndax Pharmaceuticals Company Profile

(Get Rating)

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML); and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD).

See Also

Receive News & Ratings for Syndax Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syndax Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.